BERNS PAUL L 4

What Happened
Paul L. Berns, Chief Executive Officer and Chairman of Neumora Therapeutics (NMRA), reported the sale of 9,819 shares on 2026-02-17. The shares were disposed of in an open-market/private sale for a weighted average price of $3.51 per share, totaling roughly $34,459. The filing indicates the sale was made to satisfy tax withholding obligations related to the vesting of restricted stock units (RSUs), a routine, non-investment-driven transaction.

Key Details

• Transaction date: 2026-02-17; Form 4 filed: 2026-02-19 (timely).
• Type: Sale to satisfy tax withholding from RSU vesting. Transaction code: S / withholding (F).
• Shares sold: 9,819; weighted average price reported: $3.51; total proceeds ≈ $34,459.
• Price range: trades executed at prices from $3.48 to $3.545; weighted average shown ($3.51). Reporting person can provide per-trade breakdown on request (footnote F2).
• Shares held by trusts referenced in the filing: LULU TRUST OF 2024 FBO AB, OB, and HB (footnotes F3–F5).
• Shares owned after the transaction: not specified in the provided filing.

Context
This sale was reported as a tax-withholding disposition tied to RSU vesting — a common administrative sale that does not necessarily signal insider sentiment about the company's prospects. For retail investors, purchases typically carry more interpretive weight than routine withholding sales. The filing appears timely (within the Form 4 two-business-day window).